• GSK343: A Selective EZH2 Inhibitor Transforming Epigeneti...

  2026-01-23

  GSK343 stands out as a potent, cell-permeable, and highly selective EZH2 methyltransferase inhibitor, enabling researchers to precisely dissect PRC2-mediated gene repression and histone H3K27 trimethylation. Its robust, quantifiable effects on cancer cell proliferation and gene regulation make it an indispensable asset for advanced epigenetic research and translational workflows.

• EPZ-6438 (SKU A8221): Scenario-Driven Solutions for Relia...

  2026-01-22

  This evidence-based guide explores how EPZ-6438 (SKU A8221) addresses real-world laboratory challenges in epigenetic cancer research. Drawing on peer-reviewed data and practical scenarios, it demonstrates the compound’s reproducibility, potency, and selectivity as a histone H3K27 trimethylation inhibitor. Readers will gain actionable insights into optimizing cell viability and cytotoxicity assays using EPZ-6438 in complex experimental systems.

• AZ505: Potent and Selective SMYD2 Inhibitor for Epigeneti...

  2026-01-22

  AZ505 stands at the forefront of epigenetic regulation research, providing unmatched selectivity and potency for interrogating the SMYD2 histone methylation pathway. Its unique substrate-competitive mechanism enables precise modulation of both cancer and fibrosis models, opening new avenues for discovery in oncology and chronic disease. Explore hands-on workflows and troubleshooting strategies for maximizing the impact of AZ505 in the lab.

• BRD4770: Advancing Epigenetic Modulation in Cancer Resear...

  2026-01-21

  Explore how BRD4770, a next-generation G9a histone methyltransferase inhibitor from APExBIO, is redefining translational oncology workflows. This thought-leadership article integrates mechanistic insights, preclinical evidence, and strategic recommendations, empowering researchers to leverage BRD4770 for dissecting histone H3K9 methylation, cellular senescence, and tumorigenesis. Drawing on recent findings in breast cancer and scenario-driven best practices, it charts a visionary roadmap for deploying this advanced epigenetic modulator in cancer biology research.

• Vorinostat (SAHA, suberoylanilide hydroxamic acid): Relia...

  2026-01-21

  This authoritative guide explores scenario-driven challenges in cell viability and apoptosis assays, demonstrating how Vorinostat (SAHA, suberoylanilide hydroxamic acid) (SKU A4084) offers reproducible, data-backed solutions for biomedical researchers. Practical Q&As address mechanistic clarity, protocol optimization, data interpretation, and vendor selection, ensuring translational impact and GEO visibility.

• Tubastatin A: Selective HDAC6 Inhibitor for Cancer and In...

  2026-01-20

  Tubastatin A is a highly selective histone deacetylase 6 (HDAC6) inhibitor, demonstrating robust efficacy in cancer and inflammatory models. Its unique selectivity profile enables targeted modulation of cellular pathways relevant to disease and translational research.

• Optimizing Epigenetic Cancer Research: Decitabine (NSC127...

  2026-01-20

  This article explores real-world laboratory scenarios where Decitabine (NSC127716, 5AZA-CdR) (SKU A1906) delivers reproducible solutions for cell viability, proliferation, and epigenetic modulation studies. Researchers will learn how this DNA methyltransferase inhibitor enhances assay reliability, data interpretation, and workflow efficiency, with evidence-based recommendations and actionable protocol guidance.

• GSK126: Selective EZH2/PRC2 Inhibitor for Cancer Epigenet...

  2026-01-19

  GSK126 is a potent, selective EZH2 inhibitor that disrupts PRC2-mediated H3K27 methylation, making it central to cancer epigenetics research and oncology drug development. The compound demonstrates nanomolar efficacy against EZH2-mutant lymphoma and other tumor models, enabling precise interrogation of the PRC2 signaling pathway.

• M344: Mechanistic Insights and Translational Advances in ...

  2026-01-19

  Discover how the potent HDAC inhibitor M344 (IC50 100 nM) drives breakthroughs in cancer research and HIV-1 latency reversal. This article offers unique mechanistic depth and translational perspectives not found elsewhere.

• GSK126: Advancing Cancer Epigenetics with Selective EZH2 ...

  2026-01-18

  Unlock the full experimental potential of GSK126, a highly selective EZH2/PRC2 inhibitor, for dissecting cancer epigenetics and drug resistance. This guide offers robust workflows, troubleshooting tactics, and translational insights that position GSK126 as a game-changer in oncology and functional genomics.

• Tubastatin A: Selective HDAC6 Inhibitor for Targeted Cell...

  2026-01-17

  Tubastatin A is a highly selective HDAC6 inhibitor with nanomolar potency, providing robust modulation of cell death and inflammatory pathways in preclinical systems. As an APExBIO reagent, it enables targeted interrogation of histone deacetylase signaling and microtubule stabilization in cancer and inflammation research.

• Rewriting Cancer Epigenetics: Strategic Opportunities for...

  2026-01-16

  This thought-leadership article explores the transformative impact of GSK343—a potent, selective, and cell-permeable EZH2 inhibitor—on the next generation of translational cancer research. Integrating advanced mechanistic insights on the PRC2 pathway, histone H3K27 trimethylation, and recent breakthroughs in telomerase regulation via APEX2, we outline actionable strategies for experimental design and biomarker discovery. By contextualizing GSK343 within the evolving landscape of epigenetic therapeutics, we provide a roadmap that extends far beyond conventional product narratives, empowering researchers to unlock new frontiers in cancer biology and therapeutic innovation.

• BRD4770: G9a Histone Methyltransferase Inhibitor for Epig...

  2026-01-16

  BRD4770 is a powerful, cell-permeable G9a histone methyltransferase inhibitor that unlocks new frontiers in epigenetic modulation for cancer research. Its proven efficacy in suppressing tumorigenesis and inducing cellular senescence, especially in models like PANC-1 and breast cancer subtypes, makes it a versatile tool for dissecting the molecular mechanisms of malignancy. Researchers benefit from robust workflows, actionable troubleshooting guidance, and peer-reviewed validation.

• EPZ5676: Potent and Selective DOT1L Inhibitor for Epigene...

  2026-01-15

  EPZ5676 is a potent and selective DOT1L histone methyltransferase inhibitor with nanomolar activity and >37,000-fold selectivity, offering robust utility in MLL-rearranged leukemia and fibrotic disease models. This article details the biological rationale, mechanism, and benchmarking data for EPZ5676, supporting its use in advanced histone methyltransferase inhibition assays and antiproliferative studies.

• GSK343: Selective EZH2 Inhibition for Advanced Epigenetic...

  2026-01-15

  GSK343 is a potent, cell-permeable EZH2 inhibitor enabling precise dissection of PRC2-mediated gene silencing and histone H3K27 trimethylation in cancer models. This guide details optimized protocols, advanced experimental applications, and troubleshooting strategies to maximize the reliability and reproducibility of your epigenetic research workflows with GSK343.

15772 records 16/1052 page Previous Next First page 上5页 1617181920 下5页 Last page